| Abstract [eng] |
The aim of the study was to investigate how the immunophenotyping of malignant plasma cells using flow cytometry could be used for the prognosis of multiple myeloma recurrence, evaluation of disease aggressiveness based on the formation of circulating plasma cells (CPCs) in peripheral blood, and optimization of minimal residual disease (MRD) testing by harmonizing the immunophenotyping analysis strategy. It was found that a decrease in the expression of adhesion molecules leads to the formation of CPCs in bone marrow - patients with CPCs had weaker expression of CD38, CD49d, CD49e, CD56, and CD138, and the expression was even weaker in the CPCs themselves. It was also found that a significant decrease in CD38 expression at diagnosis leads to shorter overall survival, and a decrease in CD27, CD56, CD117, and CD138 expression is associated with high-risk chromosomal abnormalities in malignant plasma cells. In addition, harmonization of the MRD analysis algorithm was performed in different research centers, and it was found that a unified algorithm reduces data variation, and flow cytometry criteria for evaluating the quality of bone marrow aspirate (mast cell, hematogone, and myeloid precursor cell counts) allow the assessment of sample suitability for MRD testing. |
